Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Flagstar Bank NA (FLG) vs Moderna, Inc. (MRNA) Price & Performance

Flagstar Bank NATrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Flagstar Bank NA vs Moderna, Inc. — how do they compare? Flagstar Bank NA trades at $14.26 (market cap $5.89B), while Moderna, Inc. trades at $63.6 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 4.1× Flagstar Bank NA's market cap, and Flagstar Bank NA pays a 0.28% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

FLGMRNA
Market Cap
$5.89B$24.18B
Sector
FinancialsHealth
52-Week High
$15.36$81.80
52-Week Low
$10.72$22.36
Dividend Yield
0.28%
Enterprise Value
$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Flagstar Bank NA

Flagstar Bank (FLG) trades at $14.285, up 1.96% today, with a bullish technical signal from moving averages and a consensus analyst price target of $16.85. Recent Q2 2026 earnings missed estimates, but the bank reported its third consecutive profitable quarter, supported by loan growth and cost controls. A $250 million share repurchase program and dividend payments reflect strong capital management, while proprietary technology initiatives aim to bolster long-term growth.

The outlook is cautiously optimistic, with potential upside from execution on strategic initiatives and valuation support from a low P/B ratio of 0.77. Risks include earnings volatility, competitive pressures in regional banking, and sensitivity to interest rate changes. Analyst sentiment is positive with no sell ratings, but investors should monitor fee income trends and credit quality.

Moderna, Inc.

Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.

Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.

Returns comparison

Trailing returns across standard periods

About Flagstar Bank NA

Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.

Read more on FLG

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA